CoChat

Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice

Open access
Dumont, Magali, Stack, Cliona, Elipenahli, Ceyhan, Jainuddin, Shari, Gerges, Meri, Starkova, Natalia, Calingasan, Noel Y., Yang, Lichuan, Tampellini, Davide, Starkov, Anatoly A., Chan, Robin B., Di Paolo, Gilbert, Pujol, Aurora, Beal, M. Flint · 2012 · Human Molecular Genetics
Cited by 78

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Peroxisome proliferator-activated receptors (PPARs) are ligand-mediated transcription factors, which control both lipid and energy metabolism and inflammation pathways. PPARγ agonists are effective in the treatment of metabolic diseases and, more recently, neurodegenerative diseases, in which they show promising neuroprotective effects. We studied the effects of the pan-PPAR agonist bezafibrate on tau pathology, inflammation, lipid metabolism and behavior in transgenic mice with the P301S human tau mutation, which causes familial frontotemporal lobar degeneration. Bezafibrate treatment significantly decreased tau hyperphosphorylation using AT8 staining and the number of MC1-positive neurons. Bezafibrate treatment also diminished microglial activation and expression of both inducible nitric oxide synthase and cyclooxygenase 2. Additionally, the drug differentially affected the brain and brown fat lipidome of control and P301S mice, preventing lipid vacuoles in brown fat. These effects were associated with behavioral improvement, as evidenced by reduced hyperactivity and disinhibition in the P301S mice. Bezafibrate therefore exerts neuroprotective effects in a mouse model of tauopathy, as shown by decreased tau pathology and behavioral improvement. Since bezafibrate was given to the mice before tau pathology had developed, our data suggest that bezafibrate exerts a preventive effect on both tau pathology and its behavioral consequences. Bezafibrate is therefore a promising agent for the treatment of neurodegenerative diseases associated with tau pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/dds355

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 24 references

Cited by

See all 78

Metadata

Authors
Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N., Calingasan, N. Y., Yang, L., Tampellini, D., Starkov, A. A., Chan, R. B., Di Paolo, G., Pujol, A., & Beal, M. F.
Venue
Human Molecular Genetics
Published
2012-08-24
Volume
21
Issue
23
Pages
5091-5105
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2168842577
Cited by
78
References
24
FWCI
3.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. https://app.cochat.ai/papers/10.1093/hmg/dds355
The paper
Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N., Calingasan, N. Y., Yang, L., Tampellini, D., Starkov, A. A., Chan, R. B., Di Paolo, G., Pujol, A., & Beal, M. F. (2012). Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Human Molecular Genetics. https://doi.org/10.1093/hmg/dds355

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.